
    
      Part 1A is a dose escalation study in patients with small cell lung cancer or large cell
      neuroendocrine carcinoma with cytologically confirmed, limited or extensive SCLC or LCNEC
      that have relapsed or refractory limited or extensive disease following no more than 2 prior
      chemotherapy regimens.

      Part 1B is an expansion study where patients will be enrolled and treated in order to further
      characterize safety and preliminary efficacy in patients with SCLC or LCNEC and further
      characterize PK, immunogenicity and target expression and possible relationship to clinical
      outcome.
    
  